Interim Postmarket Data Release May Compromise Trials – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26
You may also be interested in...
CMS Proposes National Noncoverage Of VNS Therapy For Depression
CMS plans to reject Cyberonics' request for national Medicare coverage of its VNS therapy for treatment-resistant depression, an action that would also end the firm's ability to seek coverage from local Medicare carriers
CMS Proposes National Noncoverage Of VNS Therapy For Depression
CMS plans to reject Cyberonics' request for national Medicare coverage of its VNS therapy for treatment-resistant depression, an action that would also end the firm's ability to seek coverage from local Medicare carriers
Neuronetics Anti-Depression Device Not Equivalent To Shock Therapy – Panel
Neuronetics' NeuroStar transcranial magnetic stimulation system is not substantially equivalent to electroconvulsive "shock" therapy for treatment of major depressive disorder, FDA's Neurological Devices Panel concluded Jan. 26